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Translational Relevance 
Although early detection and conventional therapies have changed the natural history of breast 
cancer, many patients die from progressive disease. Dissection of the mechanisms underlying breast 
cancer progression may identify early markers for invasive tumors as well as specific targeted 
therapeutics, providing further improvement in the clinical outcomes of patients. This study 
recognizes a novel function for phosphodiesterase (PDE) type 5 in controlling malignant breast 
epithelial cell behavior, and provides important clinical implications that can impact the prediction 
of the risk, and the treatment of breast cancer patients. First, since enhanced PDE5 expression 
promotes the invasive potential of breast cancer cells and predicts a worse survival in patients, this 
enzyme may represent a valuable molecular candidate with prognostic significance. Moreover, 
being PDE5 a known druggable target, our findings may be promising for antitumor therapy with 
reduced adverse effects. Certainly, future studies could clarify the role of PDE5 in breast cancer. 
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Abstract 
Purpose: By catalyzing cGMP hydrolysis, phosphodiesterase (PDE) 5 is a critical regulator of its 
concentration and effects in different (patho)physiological processes, including cancers. Being 
PDE5 a known druggable target, we investigated the clinical significance of its expression in breast 
cancers and the underlying mechanisms by which it may contribute to tumor progression. 
Experimental Design: PDE5 expression was evaluated in seven breast cancer cells by RT-PCR 
and immunoblotting. To examine PDE5’s impact on cancer phenotype, MCF-7 cells, expressing 
lower levels of the enzyme, were engineered to stably overexpress PDE5. Proliferation was 
evaluated by MTT assays, motility and invasion by wound-healing/transmigration/invasion assays; 
transcriptome-profiling by RNA-sequencing; Rho GTPase signaling activation by GST-pulldown 
assays and immunoblotting. Clinical relevance was investigated by immunohistochemistry on 
tissues and retrospective studies from Metabric-cohort. 
Results: PDE5 is differentially expressed in each molecular subtypes of both breast cancer cell 
lines and tissues, with higher levels representing a startling feature of HER2-positive and triple-
negative breast cancers. A positive correlation was established between elevated PDE5 levels and 
cancers of high-histological grade. Higher PDE5 expression correlated with shorter patient survival 
in retrospective analyses. On molecular level, stable PDE5 overexpression in Luminal-A-like MCF-
7 cells resulted in enhanced motility and invasion through Rho GTPase signaling activation. 
Treatment of PDE5-stable clones with selective ROCK or PDE5 inhibitors completely restored the 
less motile and weak invasive behavior of control-vector cells.  
Conclusion:  PDE5 expression enhances breast cancer cell invasive potential, highlighting this 
enzyme as a novel prognostic candidate and an attractive target for future therapy in breast cancers.  
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Introduction 
In 2012, an estimated 1,67 million new cases of invasive breast cancer were diagnosed among 
women and approximately 522,000 patients were expected to die from breast cancer world-wide 
(1). Despite advances in surgery, radiation and therapy, metastatic disease represents the most 
important contributor to breast cancer-related mortality (2). Thus, novel marker and therapeutic 
target exploration is critical to the early detection, metastasis prevention, and effective treatment of 
human breast cancers.  
Phosphodiesterases (PDEs) are metallo-hydrolases which catalyze the breakdown of cyclic 
adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) into their 
biologically inactive 5′-derivatives, thus modulating the amplitude and duration of their intracellular 
signalings. In most tissues, PDE5 is the predominant isoform responsible for cGMP hydrolysis and 
its activity is tightly controlled by cGMP itself (3). cGMP regulates a myriad of biological 
processes, including cell growth and adhesion, energy homeostasis, neuronal signaling, and muscle 
relaxation (4, 5). In addition, dysregulation of cGMP homeostasis was observed in various 
(patho)physiological conditions, including cancers. Indeed, cGMP signaling, through activation of 
downstream effectors (i.e., cGMP-dependent protein kinase G-PKG, cyclic-nucleotide-gated ion 
channels) and/or crosstalk with cAMP pathways, appears to play an important role in promoting 
apoptosis and inhibiting proliferation of certain epithelial cells (6, 7). Interestingly, PKG expression 
or cGMP levels are reduced in cancer cells and tissues compared to their normal counterparts (8, 9). 
In the last ten years, overexpression of PDE5 has been described in multiple human carcinomas, 
including bladder, lung and breast cancers (10-13). The increased expression of PDE5 in human 
malignancies coupled with the efficacy and high tolerability profiles of PDE5 inhibitors (i.e. 
sildenafil and vardenafil) in the treatment of erectile dysfunction and pulmonary hypertension have 
led to an increased interest in investigating PDE5-targeted drugs in cancer management (14, 15). 
Indeed, several in vitro observations have shown anti-proliferative and pro-apoptotic effects of 
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PDE5 inhibitors in cancer cell lines, as those of the breast (13, 14, 16, 17). Another PDE5 inhibitor, 
the nonsteroidal anti-inflammatory drug exisulinid inhibited growth and induced apoptosis in 
human tumor cells through cGMP elevation and PKG activation (12, 18, 19). PDE5 inhibitors also 
increased the efficacy of chemotherapy agents in cancer models (20). Recently, it has been reported 
that modulation of host immune response represents an additional mechanism by which PDE5 
inhibitors may block tumor progression (21). However, despite these studies, neither the expression 
of PDE5 in breast cancer cell lines and tissues nor the underlying regulatory molecular mechanisms 
by which PDE5 expression may contribute to breast cancer progression have been deeply studied. 
Being PDE5 a well-characterized druggable target, in this study we propose to examine PDE5’s 
impact on breast cancer phenotype in vitro, as well as to assess its clinical relevance in breast cancer 
patients.  
 
Materials and Methods 
Reagents, antibodies and plasmids  
Sildenafil/Y-27632 were from Sigma; PDE5A/p-c-MycThr58/Ser62/c-Myc/p-IκB-αSer32/36/IκB-α/NF-
kBp65/Laminb/GAPDH antibodies from Santa Cruz Biotechnology; RhoA-C/Cdc42/Rac1-3 from 
Life Technologies; Cofilin activation/Myosin Light Chain 2 antibody sampler kits from Cell 
Signaling. pEGFP-C1 vector and the fusion protein expression vector pEGFP-PDE5A were 
provided by Dr F. Barbagallo (Sapienza-University, Rome-Italy). Scrambled and 4-unique 29mer 
PDE5A shRNA constructs in pGFP-C-shLenti vector were from Origene.  
 
Cell culture 
MCF-7/T47D/ZR-75/SKBR3/BT-20 and MDA-MB-468/MDA-MB-435 breast cancer cell lines 
were from American-Type-Culture-Collection and Interlab-Cell-Line-Collection, respectively, 
where they were authenticated, stored following suppliers and used within six-months after frozen-
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aliquot resuscitations. To generate PDE5A-overexpressing MCF-7 cells, cells were transfected with 
pEGFP-PDE5A vector using Fugene6-reagent (Promega). Stable clones were selected with G418 
antibiotic (1mg/ml, Life Technologies), and positive clones were identified using fluorescence 
microscopy and immunoblot analysis. Cells were authenticated, every six-months (last examined in 
February 2015), by short-tandem-repeat profiling, morphology, doubling-times, and tested for 
mycoplasma-negativity (MycoAlert, Lonza).  
 
Transient transfection 
For overexpression studies, T47D cells were transfected with pEGFP-C1 or pEGFP-PDE5A 
vectors and for gene silencing, MDA-MB-468 cells with scrambled or PDE5A shRNA constructs 
using Fugene6. After 48h, cells were harvested and used in different experimental procedures. 
 
RT-PCR assays 
PDE5 and 36B4 gene expression were evaluated by reverse transcription (RT)-PCR method as 
described (22). Primers: forward 5’-ACTTGCATTGCTGATTGCTG-3’ and reverse 5’-
TTGAATAGGCCAGGGTTTTG-3’ (PDE5A); forward 5’-CAAATCCCATATCCTCGTCC-3’ and 
reverse 5’-CTCAACATCTCCCCCTTCTC-3’ (36B4). 
 
Immunoblot analysis 
Cell extracts were resolved by SDS-PAGE, as described (22). Immunoblots show a single 
representative of three-separate experiments. 
 
Fluorescence microscopy 
Cells were fixed with 4% paraformaldehyde and permeabilized with PBS+0.2% TritonX-100. 
4’,6-Diamidino-2-phenylindole (DAPI, Sigma) was used for nuclei detection. Fluorescence was 
photographed with OLYMPUS-BX51 microscope, 100X-magnification. 
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MTT cell proliferation assays  
Three days after seeding, cell proliferation was assessed using 3-[4,5-Dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium bromide reagent/MTT (Sigma) and expressed as fold change relative to empty 
vector-transfected cells. Data represent three-independent experiments, performed in triplicate. 
 
Wound-healing assays 
Cell monolayers were scraped and subjected to various experimental conditions. Wound closure 
was monitored over 24h, cells were fixed and stained with Comassie-Brillant-Blue. Pictures 
represent one of three-independent experiments (10X-magnification, phase-contrast microscopy). 
 
Transmigration assays 
Cells under the various experimental conditions were placed in upper compartments of Boyden-
chambers (8µm-membranes, Corning). Bottom well contained regular-growth media. After 24h, 
migrated cells were fixed and stained with DAPI. Migration was quantified by viewing five-
separate fields/membrane (10X-magnification) and expressed as mean numbers of migrated cells. 
Data represent three-independent experiments, assayed in triplicate. 
 
Invasion assays 
Matrigel-based invasion assay was performed in Boyden-chambers (8µm-membranes) coated 
with Matrigel (BD Bioscences, 0.4µg/ml), as described (23). After 24h, invaded cells were 
quantified as reported for transmigration assays.  
 
RNA library preparation and sequencing 
Total RNA was extracted from vector- and PDE5-expressing cells and libraries were prepared 
and sequenced as described in Supplementary Materials and Methods. 
Research. 
on December 17, 2015. © 2015 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on December 14, 2015; DOI: 10.1158/1078-0432.CCR-15-1900 
8 
 
 
Rho GTPase activation assays 
Rho GTPases activation was determined by active Rho and Cdc42 pull-down and detection kits, 
following manufacturers (Life Technologies).  
 
Phalloidin staining  
Polymerized actin stress fibers were stained with Alexa Fluor 568-conjugated phalloidin, 
following manufacturers (Life Technologies). Cell nuclei were counterstained with DAPI. 
OLYMPUS-BX51 microscope (100X-magnification) was used for imaging. 
 
Patients and tissue specimens 
A total of 35 primary breast carcinomas and three non-neoplastic breast tissues were analyzed in 
this study. These carcinomas were obtained from patients who had undergone initial surgery and 
signed informed consent between 2012-2014 at Annunziata Hospital (Cosenza, Italy). The patients' 
age at diagnosis varied from 33 to 85 years (mean, 60.6 years; median, 57 years). Characteristics of 
the patient cohort are reported in Supplementary Table 1. Fresh tissues were formalin-
fixed/paraffin-embedded after surgical removal. Sections were stained with H&E to select samples 
consisting of at least 50% tumor cells and to establish the histologic type and grade (Supplementary 
Table 1). The clinical investigation conformed the Declaration of Helsinki of 1975 and was 
approved by ethics and institutional human subjects committees at Annunziata Hospital. 
 
Classification of molecular subtypes 
In breast cancer, immunohistochemistry has been used as a surrogate for molecular classification by 
gene expression profiling in large population-based studies, showing an acceptable level of 
accuracy for determining molecular phenotypes (24-26). Breast subtype classification is described 
in Supplementary Materials and Methods. 
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Immunohistochemical analysis 
PDE5A expression in non-neoplastic and neoplastic breast tissues was detected as described in 
Supplementary Materials and Methods. 
 
Database setup for retrospective study 
The entire database contains 1988 patients (average overall survival: 8.07 years, ER-positive 
patients: 76%, lymphnode-positive patients: 47.3%). Illumina gene-chips published by the 
Metabric-consortia were downloaded from the EGA repository (27). The raw gene-chip data were 
imported into R and summarized using beadarray package (28). Quantile normalization was 
performed using preprocessCore package (29).  
 
Statistical analysis  
Data were analyzed for statistical significance using two-tailed student’s Test, GraphPad-Prism4. 
Standard deviations/S.D. are shown. For RNA sequencing bioinformatics analysis, sequencing 
reads (50-60 million reads/sample on average) were trimmed, quality filtered and aligned, including 
junction-spanning reads back, to the human genome hg19 (Homo sapiens Ensembl GRCh37) using 
Tophat v.2.0.10 (30).  HTSeq (31) was used to compute read counts across each gene, which were 
then used as input to R package DESeq2 (32). DESeq2 was used to normalize read counts for 
library size and dispersion followed by tests for differential gene expression. Significant 
differentially expressed genes were determined using false discovery rate (FDR) cutoff ≤ 0.05 and 
at least 1.5-fold change between conditions. Functional analyses were performed with Ingenuity 
Pathway Analysis suit (Ingenuity Systems). For immunohistochemistry, the correlations between 
PDE5 and grading/ER/PR/HER2 status were examined with Mann-Whitney-U test, between PDE5 
and breast cancer subtypes by Kruskal-Wallis test (GraphPad-Prism4). Kaplan-Meier survival plot, 
hazard ratio with 95% confidence intervals and logrank P value were calculated and plotted in R as 
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described (33). Cox proportional hazard regression was computed to compare the association 
between gene expression, clinical variables including ER/HER2/lymphnode status and survival in 
multivariate analysis using WinSTAT 2014 for Microsoft Excel (Robert Fitch Software). Statistical 
significance was set at p<0.05. 
 
Results  
PDE5 expression varies among different breast cancer cell subtypes. 
On the basis of gene expression signatures in breast cancer patients, researchers have currently 
identified at least four major molecular and clinically distinct subtypes of neoplasm: Luminal A 
(ER-positive) and B (ER-positive/HER2-enriched), HER2-positive and basal-like (34, 35). Thus, 
we first aimed to evaluate mRNA and protein expression levels of PDE5 in breast cancer cell lines 
of different molecular subtypes (n=7) (36, 37) by RT-PCR and immunoblot analyses. As shown in 
Fig. 1A and B, PDE5 expression was detected at very low levels in luminal A-type (MCF-7/T47D) 
breast cancer cells. Luminal B-like (ZR-75) cells exhibited a modest induction in PDE5 expression 
in respect with Luminal A-like cells. Notably, higher PDE5 levels were observed in HER2-
overexpressing (SKBR3) and basal-like (BT-20/MDA-MB-468/MDA-MB-435) breast cancer cells. 
These results may suggest that high PDE5 expression may be associated with more aggressive 
breast cancer phenotypes. 
 
PDE5 overexpression affects motility and invasion of MCF-7 breast cancer cells.  
In order to explore PDE5’s role in breast cancer growth and progression, a breast tumor cell line 
that expresses the lowest levels of this enzyme, MCF-7, was chosen to generate breast cancer in 
vitro models exhibiting forced PDE5 overexpression. For direct visualization of PDE5 cellular 
location, the corresponding cDNA was cloned in frame with enhanced-green-fluorescent-protein 
(EGFP) in the mammalian expression vector pEGFP-C1 and stable clones were screened using 
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fluorescence microscopy (Fig. 1C). Parental MCF-7 breast cancer cells are shown along with one 
clone stably expressing EGFP (MCF-7 e.v.) and three clones expressing cytoplasmic EGFP-PDE5 
(PDE5 1/2/3). This was further evaluated by immunoblotting detection, showing the presence of an 
exogenous PDE5 band (EGFP-tagged, ~125 kDa) in protein extracts from PDE5-overexpressing 
cells (Fig. 1D).  We used these experimental models to first investigate whether PDE5 
overexpression may cause any changes in cellular phenotypes, including proliferation, migration, 
and invasion. Anchorage-dependent growth assays revealed a slight, but significant increase in cell 
proliferation in all three PDE5 clones compared to vector-expressing cells (Fig. 1E). We then 
evaluated the ability of PDE5 overexpression to influence cell migration in wound-healing scratch 
assays and found that PDE5-expressing cells moved the farthest in either direction to close the gap 
compared with vector-expressing cells (Fig. 1F). Given the evident enhancement of motility in 
PDE5-overexpressing cells, the capacity of cells to migrate across uncoated membrane in 
transmigration assays or invade an artificial basement membrane Matrigel in invasion assays was 
tested. Although vector-expressing cells exhibited little motile and no invasive behavior in vitro, 
our data clearly showed that PDE5 overexpression significantly increased both motility and 
invasion of MCF-7 cells (Fig. 1G and H).  
To evaluate the effects of PDE5 inhibition on breast tumor cell migratory and invasive 
properties, cells were treated with the specific PDE5 inhibitor sildenafil (Fig. 2A-C). We found that 
sildenafil treatment was able to completely restore in PDE5 1/2/3 clones the less motile and weak 
invasive behavior similar to that of control MCF-7 e.v. cells. Interestingly, although at less extent, 
sildenafil caused a significant decrease in motility and invasion of vector-expressing cells (by 73% 
and 65%, respectively). This may suggest that PDE5 activity is required for controlling migration 
and invasion processes also of malignant breast epithelial cells expressing low levels of the enzyme.  
 
Role of PDE5 in motility and invasion of T47D and MDA-MD-468 breast cancer cells.  
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To extend the results obtained, we transfected vector and PDE5-expression plasmids in T47D 
luminal A-like breast cancer cells (Fig. 3A). As previously shown for MCF-7 cells, we found a 
significant increase in both migratory and invasive cell potential when PDE5 was overexpressed 
and treatment with the selective PDE5 inhibitor sildenafil completely abrogated these effects (Fig. 
3B and C). Again, PDE5 inhibition was associated with a significant reduction of motility and 
invasion also in vector-expressing cells (Fig. 3B and C). In addition, as a third confirmatory model 
we silenced PDE5 expression in MDA-MB-468 breast cancer cells, that express high levels of 
PDE5 compared to MCF-7 and T47D cells (Fig. 3D). Motility and invasion were significantly 
reduced in PDE5sh-transfected cells compared to control shRNA-transfected cells (Fig. 3E and F). 
Thus, PDE5 may be an important determinant of breast tumor cell motility and invasion. 
 
PDE5-overexpressing cells exhibit increased Rho GTPase activation. 
To gain insights into the biological properties of the highly migratory and invasive PDE5-
expressing breast cancer cells, quantitative transcriptome profiling of vector- and PDE5-
overexpressing MCF-7 cells was carried out by RNA-sequencing analysis. Comparison of the 
whole transcriptome of the two cell models revealed 4425 differentially expressed genes 
(FDR<0.05), of which 611 were up-regulated and 468 were down-regulated in response to PDE5 
overexpression (fold change≥1.5, Supplementary Table 2). These genes were next subjected to 
Ingenuity Pathway Analysis (IPA) to rank enriched biological processes (Fig. 4A), and to calculate 
the activation z-score of molecular and cellular functions and pathways (Fig. 4B and C). In line with 
our previous experiments, cellular movement was the most significantly overrepresented biological 
process in PDE5-expressing cells. In addition, many differentially-expressed genes were involved 
in cell death and survival, cell-to-cell signaling and interaction, cell growth and proliferation, 
cellular development, thus concurring to identify the five top enriched functional categories in 
PDE5 clones (Fig. 4A). Interestingly, analyzing the functions involving differentially-expressed 
genes, migration of cells and cell movement resulted to be highly activated by PDE5 
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overexpression (Fig. 4B). Then, considering the most affected pathways by PDE5 overexpression, 
we found marked changes in the activity of Rho GTPase family, with RhoA, Cdc42 and Rac 
signalings showing activation z-score of 1.9, 1.342, and 0.302, respectively (Fig. 4C). The predicted 
activation of these canonical pathways was confirmed using molecule activity predictor analysis of 
IPA (Fig. 4D and Supplementary Fig. 1). An enriched Rho GTPases signaling profile is consistent 
with the enhanced migration and invasion capabilities of PDE5-expressing cells, as these proteins 
are known to govern cell cytoskeleton organization, migration, and metastasis dissemination (38). 
To validate the gene expression profile identified by RNA sequencing, we compared expression and 
activation of Rho family of GTPases in vector and PDE5 clones. Increased protein levels of Rho A-
C, Cdc42 and Rac 1-3 (Fig. 5A, input panel) along with increased levels of activated forms (Fig. 
5A, GTP-bound panel) were detected in PDE5-overexpressing cells. In the GTP-bound form, these 
proteins are able to interact with effector molecules (i.e. mainly the Rho kinase ROCK and the p21-
activated kinase PAK1) to induce phosphorylation of LIM Kinase (LIMK), which is able to inhibit 
(by phosphorylation) Cofilin, leading to stabilization of filamentous actin structures (39). ROCK 
has also been shown to phosphorylate the regulatory Myosin Light Chain (MLC), which enhances 
its binding to F-actin (40). Consistent with increased Rho GTPase activation, the levels of 
phosphorylated LIMK, Cofilin and MLC are greatly increased in PDE5 clones compared to e.v. 
cells (Fig. 5B and C). Among other downstream targets of Rho signaling, c-Myc and NF-κB are 
important for cell motility and invasion (39, 41, 42). In PDE5-overespressing cells, we detected 
elevated levels of the activated form of c-Myc (phospho c-Myc), whereas we did not observe NF-
κB activation, as evidenced by no changes in phosphorylation of the inhibitor of NF-κB IκBα as 
well as in NF-κB nuclear translocation (Supplementary Fig. 2). To further investigate the role of 
Rho GTPases activation on cytoskeletal organization in our model systems, we evaluated the 
formation of stress fibers, since they provide the contractile force required for motility (Fig. 5D). In 
vector-expressing cells, actin filament remained diffusely distributed in the cytoplasm; while 
overexpression of PDE5 resulted in visible stress fibers. According to these results, treatment with 
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the selective ROCK inhibitor Y-27632 was able to significantly reduce both migration and invasion 
of PDE5 clones (Fig. 5E and F). Collectively, our data strongly suggest that the molecular and 
cellular functions identified with IPA are biologically relevant and PDE5 may regulate motility and 
invasion through activation of the Rho family of GTPases. 
 
PDE5 expression in human breast cancers. 
To evaluate the clinical significance of PDE5 in human breast tumors, we analyzed its 
expression levels in patient-derived tissues (n=35) by immunohistochemistry analysis. The 
characteristics of all patients are listed in Supplementary Table 1. We found that ~85% of cases 
showed cytoplasmic staining for PDE5 in cancer cells. Interestingly, ER/PR-positive tumors 
exhibited weak (n=5) or intermediate (n=15) PDE5 staining, while the strongest staining intensity 
was observed among HER2-positive or triple negative (TN) samples (n=15). In contrast, in non-
neoplastic (NN) breast tissues (n=3), a weak to missing PDE5 expression was detected in the 
cytoplasm. Representative images of PDE5 staining patterns are shown in Figure 6A. Accordingly, 
PDE5 expression had a significant inverse correlation with ER and PR status (Fig. 6B and C) and a 
significant positive correlation with HER2 status (Fig. 6D). Of note, as the staining intensity of 
PDE5 increases, grading of cancer cells also tended to increase (p = 0.001), indicating that the 
higher expression of PDE5 might be related with a higher malignancy phenotype.  
We then correlated PDE5 expression with the different subtypes of breast carcinoma and found 
that its cytoplasmic expression was significantly different among the four molecular subtypes (Fig. 
6E). In particular, in HER2 and triple-negative subtypes, PDE5 expression was the highest, 
followed by the luminal B-type and the luminal A-type, that showed the lowest percentage of cells 
with PDE5 expression. Since HER2 and TN types are correlated with a generally more aggressive 
tumor phenotype and poorer prognosis (26), these results suggest that PDE5 overexpression may be 
correlated with poor prognosis. 
 
Research. 
on December 17, 2015. © 2015 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on December 14, 2015; DOI: 10.1158/1078-0432.CCR-15-1900 
15 
 
High levels of PDE5 are associated with shorter survival in breast cancer patients. 
To strengthen the results obtained in human breast tumor tissues, we conducted retrospective 
analyses of the correlation between PDE5 expression and survival in patients with breast cancer. In 
the univariate analysis, the Kaplan-Meier overall survival (OS) curve obtained from a cohort of 
1988 patients indicated that increased expression levels of PDE5 are associated with a statistically 
significant shorter OS when compared to those tumors expressing low levels of PDE5 (p=0.014, 
HR=1.2, Fig. 6F). Interestingly, significant difference could also be observed between OS for ER-
positive patients having high or low PDE5 levels (p=7.4E-04, HR=1.4, Fig. 6G), suggesting a role 
for PDE5 in predicting disease progression in ER-positive tumors that according to 
immunohistochemistry may have lower levels of the enzyme compared to ER-negative ones. In 
addition, PDE5 retained its significance when performing a multivariate analysis including PDE5 
expression, ER, HER2 and lymphnode status in the entire database (PDE5: p=6.6E-03, HR=1.24, 
ER status: p=6.6E-05, HR=0.69, HER2 status: p=1E-05, HR=1.6, lymph node status: p=1.1E-06, 
HR=2.24). Therefore, high levels of PDE5 expression may independently predict poor outcome 
among breast cancer patients.   
 
Discussion 
Despite vast improvement in the overall survival rate of breast cancer patients, advanced 
metastatic disease remains a life-threatening stage of cancer. One of the major challenges in 
mammary cancer research is to identify key proteins that are directly involved in pathways 
promoting tumorigenesis and tissue invasion. These proteins can then be explored as early markers 
for invasive tumors as well as potential targets for the development of therapeutic strategies aimed 
at controlling and curing malignant disease. In this report, we show that phosphodiesterase type 5 
(PDE5) is differentially expressed in human breast cancer subtypes, with a significant positive 
correlation with tumor grading. Importantly, high PDE5 levels predict a worse prognosis for 
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patients at 8-year median follow-up. In experimental breast cancer models, PDE5 overexpression 
increased motile and invasive properties of cells through activation of the Rho family of GTPases, 
highlighting the potential benefit of therapeutic targeting PDE5.  
Breast cancer is a complex and highly heterogeneous disease due to its diverse morphological 
features, variable clinical outcomes and disparate therapeutic responses. By using hierarchical 
clustering analysis of gene expression profiling, Perou et al. were able to identify molecularly-
defined and clinically-distinct classes of breast cancer (Luminal, HER2-enriched, basal-like and 
normal-like) (34, 35). Due to the prognostic and predictive values of this molecular classification in 
clinical setting, attempts have been made to identify surrogate markers that would allow subtype 
identification using the more familiar immunohistochemical approach. Accordingly, the combined 
evaluation of histopathological grade and immunohistochemical parameters (ER/PR/HER2) would 
approximate the molecular classification of Luminal A, Luminal B, HER2-enriched and triple-
negative breast cancers (24-26). Despite the lack of complete overlapping, the panelists of the last 
St. Gallen Consensus have endorsed the use of the immunohistochemical assays to identify breast 
cancer subtypes and allow the physicians to tailor properly the systemic interventions (43). Here, 
we found a significant increase in PDE5 expression in breast tumors when compared to non-
neoplastic breast tissues. Although ~85% of the tumor entities examined showed cytoplasmic 
staining for PDE5, our results clearly indicate that PDE5 is differentially expressed between each 
molecular breast cancer subset. In particular, the lowest expression of this enzyme is detected in the 
more favorable Luminal A subtypes of breast tumors, whereas its overexpression is closely related 
to breast cancers of high histological grade including triple-negative and HER2-positive molecular 
subtypes. Accordingly, PDE5 levels have a negative correlation with hormone receptor status, and a 
positive one with HER2 status and tumor grading. The clinical significance of PDE5 overexpression 
is strongly supported by its significant association with a shorter overall survival time in 
retrospective studies. This association is also significant in patients with ER-positive diseases, 
advocating the utility of PDE5 as a predictor of breast cancer prognosis in ER-positive tumors that 
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immunohistochemically may have lower PDE5 levels compared to ER-negative ones. In line with 
findings on patients, PDE5 expression also varies among different breast cancer cell line models. 
Taken together, our results suggest that the differential expression of PDE5 may contribute to breast 
cancer heterogeneity and, being PDE5 a known druggable target, it could help to integrate subsets 
of aggressive breast cancer into clinically meaningful subtypes.  
At the present time, the selective PDE5 inhibitors sildenafil (Viagra and Revatio-Pfizer) and 
tadalafil (Cialis-Eli Lilly; Adcirca-United Therapeutics) have Food and Drug Administration 
approval for the treatment of erectile dysfunction (ED) as well as pulmonary artery hypertension; 
whereas vardenafil (Levitra and Vivanza-Bayer) and avanafil (Stendra-Vivus) are approved only for 
ED. However, due to their favorable toxicity profile (44), these agents are being investigated in a 
wide range of other potential medical and surgical applications, including neurological and 
cardiovascular disorders, transplant and reconstructive surgery, and several clinical trials are 
currently in progress (15). In the last ten years, various PDE5 inhibitors have been also reported to 
inhibit growth and induce apoptosis in many cancer cell lines, without affecting normal epithelial 
cells (12-14, 16, 18, 19). Recently, two reports have suggested a role for PDE5 inhibition in 
influencing cancer cell motility (17, 45).  Indeed, tadalafil and sildenafil reduced the capacity of 
thyroid cancer cells to migrate at lower doses than those used to block proliferation (17). Similarly, 
down-regulation of PDE5 in the aggressive human breast cancer cell line MDA-MB-231T resulted 
in no difference in cell proliferation and reduced motility in vitro and in vivo (45). Here, we show 
that genetic and pharmacological inhibition of PDE5 significantly decreases migration and invasion 
of different human breast cancer cell lines. In contrast, overexpression of PDE5 strongly increases 
motility and invasion of MCF-7 cells and sildenafil treatment completely restores in PDE5 stable 
clones the less motile and weak invasive behavior similar to that of control cells. Interestingly, 
although at less extent, a reduction of migration and invasion was observed after treatment with 
sildenafil also in vector cells, expressing lower levels of the enzyme, further highlighting a role for 
PDE5 in controlling migration and invasion processes of malignant breast epithelial cells. Increased 
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formation of actin stress fibers and enhanced contractility are common features of motile cells in 2D 
culture conditions (46). Indeed, immunofluorescent staining of polymerized actin (F-actin) reveals 
an induced formation of stress fibers in cells bearing PDE5 overexpression. Accordingly, ingenuity 
pathway analysis on PDE5 modulated genes by RNA-sequencing highlights cellular movement as 
the most significantly represented biological process. Moreover, most of the genes differentially 
regulated by PDE5 overexpression are significantly involved in migration of cells. Taken together, 
these results indicate that PDE5 may be important for sustaining malignant motile and invasive 
behavior of breast cancers.   
The acquisition of a remodeled cytoskeleton and a motile phenotype are important steps in tissue 
invasion and metastasis establishment, and the Rho family of GTP-binding proteins have been 
reported to mediate these processes . Although at least 20 Rho family proteins have been identified 
in humans, the most widely characterized molecules for their effects on cell migration are Rho A-C, 
which regulate stress fibers and focal adhesion formation, and Rac 1-3 and Cdc42, which control 
membrane ruffling, and filopodium formation (38). In the GTP-bound form, these proteins are able 
to interact with effector molecules to regulate actin cytoskeleton assembly and organization through 
phosphorylation of specific substrates, such as Cofilin or Myosin Light Chain, as well as to 
modulate a variety of other biochemical signalings involved in cell transformation and metastasis, 
including the c-Myc pathway (39-41). In breast tumors, Rho expression and/or activity are 
frequently increased (47). On the other hand, a complex signaling interplay between cGMP and Rho 
GTPase pathways has been described. For instance, cGMP-PKG cascade inhibits RhoA in various 
cell types (48, 49). Similarly, vardenafil prevents RhoA membrane translocation/activation, and 
decreases activity of its downstream effector ROCK in human bladder smooth muscle cells, 
inhibiting endothelin-1-induced migration (50). On the molecular level, increased levels of total and 
activated Rho A-C, Cdc42 and Rac 1-3 are detected in PDE5-overexpressing cells compared with 
vector cells. Phosphorylation levels of Rho GTPase downstream targets, including LIM Kinase, 
Cofillin, Myosin Light Chain and c-Myc, are also greatly increased in PDE5 clones compared to 
Research. 
on December 17, 2015. © 2015 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on December 14, 2015; DOI: 10.1158/1078-0432.CCR-15-1900 
19 
 
vector cells. Moreover, transcriptome analysis identifies an enriched Rho GTPase signaling profile 
in PDE5-overexpressing cells. Consistent with these findings, a selective ROCK inhibitor 
significantly reduces both migration and invasion of PDE5 clones.  
In conclusion, results of this study highlight a novel role for PDE5 in controlling malignant 
breast epithelial cell behavior and provide the first indications for the clinical relevance of this 
enzyme in human breast cancers. Since PDE5 overexpression greatly enhances the invasive 
potential of breast cancer cells and reduces survival in patients, it is tempting to speculate that this 
enzyme may represent a novel prognostic biomarker candidate. In addition, having already 
addressed the delivery, stability and toxicity issues of PDE5 inhibitors in other diseases, our 
findings may offer promising insights into future cancer treatments by providing the rationale to 
implement safer and more efficacious drugs in the adjuvant therapy for improving clinical care and 
reducing mortality from breast cancer. This may assume particular significance in triple-negative 
breast cancers in which PDE5 may be an attractive target. Based on these observations, it is evident 
that the impact of PDE5 in the prediction of the risk, and the treatment of breast cancer patients 
deserves further attention.  
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Figures Legends 
  
Figure 1. Impact of PDE5 overexpression on breast cancer cell proliferation, motility and 
invasion. A, RT-PCR analysis for PDE5 and 36B4 (internal standard) mRNA levels in Luminal A-
type (MCF-7/T47D), Luminal B-like (ZR-75), HER2-overexpressing (SKBR3) and basal-like (BT-
20/MDA-MB-468/MDA-MB-435) breast cancer cells. B, Immunoblotting for PDE5 expression in 
indicated cells. GAPDH, control for loading. C, Fluorescence-microscopic analysis to visualize 
EGFP-fluorescence in MCF-7 cells stably transfected with pEGFP-C1 (e.v.) or fusion protein 
expression pEGFP-PDE5A vectors (PDE5 1/2/3). MCF-7 cells, negative control. Insets: DAPI, 
nuclear staining. D, Immunoblotting showing EGFP-PDE5 expression in e.v. and PDE5 1/2/3 
MCF-7 cells. GAPDH, control for loading. MTT growth (E), wound-healing (F, insets: time 0), 
transmigration (G) and invasion (H) assays in cells under basal nonstimulated conditions. *P<0.05, 
**P<0.005. 
 
Figure 2. Effects of sildenafil on motility and invasion of PDE5-overexpressing MCF-7 breast 
cancer cells. Wound-healing (A, insets: time 0), transmigration (B) and invasion (C) assays in cells 
treated with vehicle (-) or sildenafil (Sild, 10µM). *P<0.05, **P<0.005, ***P<0.0005. 
 
Figure 3. Influence of PDE5 on motility and invasion of T47D and MDA-MB-468 breast 
cancer cells. A, RT-PCR (upper panel) and immunoblot (lower panel) analyses for PDE5 
expression in vector (e.v.) and PDE5-expressing T47D cells. 36B4, internal standard. GAPDH, 
control for loading. Transmigration (B) and invasion (C) assays in cells treated with vehicle (-) or 
sildenafil (Sild, 10µM). D, RT-PCR (upper panel) and immunoblot (lower panel) analyses for 
PDE5 expression in MDA-MB-468 cells transfected with control scrambled-shRNA (CTRLsh) and 
PDE5 shRNA (PDE5sh) constructs. 36B4, internal standard. GAPDH, control for loading. 
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Transmigration (E) and invasion (F) assays in CTRLsh and PDE5sh transfected MDA-MB-468 
cells. **P<0.005. 
 
Figure 4. Biological processes, functions and pathways identified from RNA sequencing data in 
PDE5-overexpressing MCF-7 cells. Ingenuity Pathway Analysis (IPA) used to identify biological 
processes significantly associated with differentially-expressed genes (A) and to calculate activation 
z-score of biological functions (B) and pathways (C). D, Predicted activation of RhoA signaling 
pathway by molecule activity predictor analysis of IPA in PDE5-overexpressing versus vector-
transfected MCF-7 cells.  
 
Figure 5. Rho GTPase activation in PDE5-overexpressing cells. A, Input panel, 
immunoblotting for Rho A-C, Cdc42 and Rac 1-3 expression. GTP-bound panel, activation assays 
of Rho A-C, Cdc42 and Rac 1-3. Immunoblotting showing phosphorylated LIM Kinase 
(pLIMK1Thr508/pLIMK2Thr505), Cofilin (p-CofilinSer3) (B), Myosin Light Chain (pMLCThr18/Ser19) (C) 
and total proteins from whole-cell lysates. GAPDH, control for loading. D, Phalloidin staining of F-
actin (stress fibers, red). DAPI, nuclear staining.  Insets: Stress fibers with higher resolution. 
Transmigration (E) and invasion (F) assays in cells treated with vehicle (-) or ROCK inhibitor (Y-
27632, 10µM). *P<0.05, **P<0.005, ***P<0.0005. 
 
Figure 6. Role of PDE5 in breast cancer patients. A, Immunohistochemical detection of PDE5 
expression in nonneoplastic breast tissues (NN), ER/PR-positive (+), HER2-overexpressing (HER2) 
and triple–negative (TN) breast cancer tissues. Representative fields were photographed at 20X-
magnification (insets: details of PDE5 subcellular localization). PDE5 immunohistochemical 
expression was correlated to ER (B), PR (C), HER2 (D) status or molecular subtypes (E) of breast 
cancer patients. Kaplan-Meier survival analysis relating PDE5 levels and overall survival in all 
patients (F) or in patients with ER-positive breast cancers (G). 
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